I'd say the company has made good advancements this past year and we do have a lot of positive items on the horizon for 2024.

Did you reload your 10,000 shares b4 the spike today?

Which boys are crying wolf?

2 weeks until Thanksgiving holiday :)

dshade loves the long weekends, USA Thanksgiving is on the horizon.

Any updates from the company or the street on this stock?

Any updates from the company or the street on this stock?

Did your shares sell today already?

I think it can, I think it can.

hey, that's kadlec's patented line.

Thank you Sportynorty, good post. Can WaveRunners answer your question about, "does the entire 180 day FDA approval start all over again?"

Hi Waverunners, do you mind giving us an update on the status of the company and any anticipated dates or timelines? Thanks.

Any updates from FDA or the company? Thanks.

Can you provide the iHub UEEC members with an update on the status of this UEEC company? Are we still in the races to get the product presented to the FDA, what is the status on this? Thanks!

Which broker do they use?

Which MM route are you bidding through?
ETRF
GTSM
INTL
OTCN
PUMA
CDEL
NITE

I can smell what The Rock is cooking!

Nobody is hungry. Everyone ate their fill. Gobble gobble.

VWAP pre-split is $0.0159 on 2.47m volume (Sept07-2023). $SKYED post split equal value to yesterday's trading would be $3.98 per share. Slightly undervalue today, could be an opportunity to get cheap and discounted shares.

Reverse Stock Split to Be Effective on September 8th
Press Release | 09/07/2023
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, announced today that the previously announced 1-for-250 reverse stock split of its issued and outstanding common stock will become effective on Friday, September 8th. Skye's common stock is expected to begin trading on a split-adjusted basis when the market opens on Friday, September 8th. Skye will continue to trade on the OTCQB® Market under the symbol SKYE, although the letter "D" will be temporarily appended to the ticker symbol for twenty (20) trading days following the reverse split.

As a result of the reverse stock split, each 250 pre-split shares of common stock outstanding will automatically be combined into one issued and outstanding share of common stock. No fractional shares of common stock will be issued as a result of the reverse stock split. Each fractional share will be rounded up to one whole share. The new CUSIP for the common stock following the reverse stock split will be 83086J200.

Following the reverse stock split, the total number of authorized shares of common stock will be 20,000,000 and approximately 12,312,551 shares of common stock will be issued and outstanding. Each stockholder's percentage ownership interest in Skye and proportional voting power will remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of common stock will be substantially unaffected by the reverse stock split. Under Nevada law, because the reverse stock split was approved by the Board of Directors of Skye in accordance with NRS Section 78.207, no stockholder approval is required.

Stockholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse stock split.

About Skye Bioscience

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor, to treat diseases with inflammatory, fibrotic, and metabolic processes. Backed by leading biotechnology venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first- and only-in-class therapeutics with significant clinical and commercial differentiation. SBI-100 Ophthalmic Emulsion is a CB1 agonist that is a potential treatment for glaucoma and is expected to start a Phase 2 clinical trial in Q4 2023. Nimacimab, a negative allosteric modulating antibody, inhibits peripheral CB1 with unprecedented safety and tolerability. A Phase 2 basket study for chronic kidney disease is expected to start in 2024. Skye is evaluating potential development paths for nimacimab related to obesity/weight loss. For more information, please visit: https://www.skyebioscience.com.

CONTACT Investor Relations Email: ir @logman

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "expects," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/179893

$ENDPQ interesting link enclosed. Since Pfizer’s smoking cessation drug Chantix was recalled in 2021, Endo's subsidiary Par Pharmaceuticals has been the only one to market the product. $PFE

https://bit.ly/3R8lufh

Endo sues Zydus in attempt to block its generic version of Chantix
By Zoey Becker
Aug 11, 2023 10:45am
ChantixEndoPar PharmaceuticalZydus
Share
A woman snaps a cigarette in half
Smoking cessation drug Chantix hit peak sales of $1.1 billion before Pfizer recalled it due to high levels of impurities. (Daria Kulkova/Getty Images)
Since Pfizer’s smoking cessation drug Chantix was recalled in 2021, Endo's subsidiary Par Pharmaceuticals has been the only one to market the product. Now, the generics subsidiary is attempting to ward off fellow generic makers who want in on the drug.

Endo's lawsuit alleges that Zydus launched its Chantix generic, which was FDA approved in June, after Endo alerted it of a new patent but before it could file a patent infringement claim. The new patent covers the method Endo uses to manufacture the drug without the impurities that took down Pfizer's original product.

RELATED
Price of Pfizer's smoking-cessation drug Chantix doubles in just 5 years: report
Chantix was originally approved in 2006. The drug was flying high with $1.1 billion in peak sales until impurities found in the product brought it crashing down. Pfizer threw in the towel and recalled all lots in September 2021, a month after the FDA cleared Endo's generic ahead of schedule.

Now, the FDA will only accept submissions for products based on Chantix’s active ingredient, varenicline tartrate, if the drugs meet the acceptable intake limit for nitrosamine impurities. That’s what Endo did, where Pfizer and others could not, according to the Aug. 8 lawsuit filed in Delaware federal court.

“Making varenicline tartrate tablets with the low levels of nitrosamine required by the FDA is difficult to do, as evidenced by the fact that Pfizer has been unable to reformulate its Chantix product to meet those requirements despite the huge incentive it has had to do so,” reads the complaint.

Endo alleges Zydus used the methods listed in its recent patent because those are “the only commercially viable methods” that it’s aware of for ensuring low levels of nitrosamine impurities.

Zydus launched its drug instead of replying to notices sent by Endo, leaving Endo unable to verify if the two companies use the same manufacturing method but finding it "highly likely," according to the complaint.

RELATED
Troubled Endo shelves cellulite treatment Qwo, lays off 90 employees
It’s likely that Endo can’t afford the generic competition after filing for bankruptcy last August due to the weight of multiple massive opioid-related settlements and $8 billion in debt. The company planned to sell itself to its senior lender group, which would then fund Endo’s opioid settlements.

The U.S. Department of Justice recently shot down that plan on the grounds of bankruptcy law violation because it would pay some creditors while others, including government agencies, would get nothing, Reuters reported.

Did Harley dump ECSL position?

Thank you for your email in advance! Finally some DD that will be true.

dazetradepennies
AT
gmail
dot
com

How can you tell if a politician is lying?

Do they know when the bankruptcy plan will be confirmed or executed?

This company still publishes news!

NEWS
THU JUL 20TH, 2023
Canada Newswire7:30 AM
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease

PR Newswire7:30 AM
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease

TUE JUL 18TH, 2023
Canada Newswire4:30 PM
Endo Launches Bivalirudin Injection in Ready-to-Use Vials

PR Newswire4:30 PM
Endo Launches Bivalirudin Injection in Ready-to-Use Vials

MON JUL 17TH, 2023
Canada Newswire4:30 PM
Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage

https://quotes.freerealtime.com/quotes/ENDPQ/Quote

Will shorts get squeezed?

Which new rules are you referring to? Thanks!

Let's all take a breath and go read "the boy who cried wolf" to remind us what we are investing in.

You are correct, new 52-week price lows today.

If retail doesn't sell, the market makers will sell into those bids and take it for themselves.

$18,000 dollar value bidder! Extremely large!

If anyone needs to pay the bills, today is the day.

Did anyone here get those $0.0211 shares filled?

Date/Time Price Shares Exch/Mkt
06/22/2023 15:25:07 EDT 0.03675 3000 OTCBB
06/22/2023 15:00:04 EDT 0.035 46100 OTCBB
06/22/2023 15:00:01 EDT 0.035 10000 OTCBB
06/22/2023 11:07:04 EDT 0.035 33900 OTCBB
06/22/2023 11:06:57 EDT 0.035 10000 OTCBB
$$$$$ 06/22/2023 10:38:58 EDT 0.0211 108500 OTCBB *$$$$$$******
06/22/2023 10:38:55 EDT 0.031 10000 OTCBB
06/22/2023 10:38:45 EDT 0.034 10000 OTCBB
06/22/2023 10:38:21 EDT 0.034 21500 OTCBB
06/21/2023 10:58:37 EDT 0.037 10000 OTCBB
06/21/2023 10:57:46 EDT 0.0355 10000 OTCBB
06/21/2023 10:57:16 EDT 0.034 10000 OTCBB
06/21/2023 10:27:10 EDT 0.0425 5000 OTCBB
06/21/2023 10:26:47 EDT 0.0425 10000 OTCBB
06/20/2023 9:30:09 EDT 0.04 4000 OTCBB
06/16/2023 15:53:03 EDT 0.037 7000 OTCBB

Have you heard any updates from the company?

I'm grinning from ear to ear, nice post! :)

Does "SHE" have more shares for sale?

What do the experts say today?
WHAT SAY YOU SONG LINK HERE:

The press release suggests the planet Mars.

Quantumkore Innovation Inc. [SBOX] Announces New Patent to Assist Future Construction on Mars
Press Release | 09/12/2022
NEW YORK, NY / ACCESSWIRE / September 12, 2022 / QuantumKore Innovation Inc. announces that it has invented and patented a nuclear-powered extrusion system for use on the Martian surface for the primary purpose of manufacturing bricks, repeated interlocking components that serve as a structural functional basis for rapid manufacturing of habitats, facilities, and other buildings necessary for colonization.

The Board believes that the results of the development team, are examples of excellence in technology, which will lead the company to the next chapters of growth and success.

Feasibility Assessment of Technical Limitations and Challenges to Deployment of a Nuclear-Powered Extrusion System on the Martian Surface

We are invited to the IEEE Aerospace Conference at the Yellowstone Conference Center in Big Sky, Montana, USA (04-11 March 2023)

The International IEEE Aerospace Conference, with AIAA[1] and PHM Society[2] as technical cosponsors, is organized to promote interdisciplinary understanding of aerospace systems, their underlying science and technology, and their applications to government and commercial endeavors. (https://aeroconf.org)

[1] AIAA = American Institute of Aeronautics and Astronautics; is a professional society for the field of aerospace engineering. The AIAA is the U.S. representative on the International Astronautical Federation and the International Council of the Aeronautical Sciences. The AIAA has earned an international reputation as the preeminent publisher of cutting-edge aerospace journals and books, and as the leading source of aerospace industry archives, dating back to the early 1900s; (https://www.aiaa.org)

[2] PHM Society = The Prognostics and Health Management Society; is a non-profit organization dedicated to the advancement of PHM as an engineering discipline; (https://phmsociety.org)

Safe Harbor Statement

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues as well as any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions.. We have incurred and will continue to incur significant expenses in our expansion of our existing business and there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional expansion of our service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

Contact Information:

info@qkinnovation.com

SOURCE: QuantumKore Inc.



View source version on accesswire.com:
https://www.accesswire.com/715082/Quantumkore-Innovation-Inc-SBOX-Announces-New-Patent-to-Assist-Future-Construction-on-Mars

Back to News Headlines

Who stated they were selling 100,000 shares?